The EMA approves Pfizer’s anti-Covid medicine

The European Agency for Medicines (EMA) announced, jeudi, avoir approuvé Pfizer’s anti-Covid medicine, the first antiviral pris par voie orale autorisé au sein de l’Union européenne.

“The EMA’s Committee for Human Usage Medicines (CHMP) has recommended the authorization of a mise sur le conditionnelle pour le medicament antiviral pris par voie orale Paxlovid”, indicated the European regulator in a communiqué, recommending “d’autoriser Paxlovid pour le traitement du Covid-19 chez les adults que n’ont pas besoin d’oxygène supplémentaire et qui present a risque accru que la maladie devienne grave”.

The EMA has scrutinized the données d’une étude impliquant des patients atteints du Covid-19 montrant que “le traitement par Paxlovid réduisait de manière significant les hospitalisations ou les décès chez les patients qui present au moins une affection sous-jacente les exposant à a risk of Covid-19 sevère”.

According to the European Agency, the majority of patients of the etude étaient infected by the Delta variant, assurant that the tests carried out in a Montrent laboratory that Paxlovid proved to be effective against Omicron.

“The EMA Committee on Human Usage and Medical has concluded that the medical benefits are superior to the risks for appropriated utilization” and will “maintain send their recommendations to the European Commission for a rapid decision applicable to all States.” members of the EU. The procedure of approval by the Commission generally applies to quelques heures or quelques jours.

Pfizer declared in December that its anti-Covid pill reduced 90% of hospitalizations and said that the people at risk were prized for the first days after the appearance of symptoms.

With the authorization of Paxlovid once a week, six anti-Covid medications are authorized by the EU therapeutic strategy board. Les États-Unis, le Canada et Israël font partie des pays ayant déjà donné leur feu vert au traitement Pfizer.

.



Source link

Leave a Comment